BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster anti-PD-1 therapy, KEYTRUDA, as a treatment for certain patients with recurrent ovarian cancer. Announced today, April 2, 2026, the approval targets adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS ≥ 1).
This regulatory milestone marks the first time a PD-1 inhibitor-based regimen has been authorized in the European Union (EU) for this notoriously difficult-to-treat patient population. By securing a foothold in the platinum-resistant setting—where therapeutic options have historically been limited to highly toxic chemotherapies—Merck not only strengthens its oncology portfolio but also builds a critical defensive moat as it prepares for the impending "patent cliff" at the end of the decade.
The KEYNOTE-B96 Breakthrough: A New Standard for Platinum Resistance
The European Commission’s decision was underpinned by robust data from the Phase 3 KEYNOTE-B96 trial (also known as ENGOT-ov65). The study evaluated KEYTRUDA in combination with paclitaxel, with or without bevacizumab, against a control arm of placebo plus chemotherapy. The results were definitive: the KEYTRUDA regimen reduced the risk of disease progression or death by 28% and the risk of death by 24% in the PD-L1 positive population (CPS ≥ 1). For a disease that often carries a grim prognosis once platinum-based therapies fail, these survival gains represent a paradigm shift in clinical management.
The timeline leading to this approval was characterized by a decade of research into the "cold" nature of ovarian tumors. Historically, ovarian cancer was thought to be less responsive to immunotherapy compared to melanoma or lung cancer. However, by identifying the PD-L1 biomarker and combining KEYTRUDA with chemotherapy to "prime" the immune system, Merck successfully cracked the code. The approval also encompasses the newly launched subcutaneous (SC) formulation of pembrolizumab, providing European healthcare providers with greater flexibility in administration and reducing the burden on infusion centers.
Initial market reactions from the European medical community have been overwhelmingly positive. Oncologists have noted that while the survival benefit is measured in months, the quality of life and the ability to avoid platinum-related toxicities for a longer duration is invaluable. For Merck, the win reinforces its status as a serial innovator, coming just weeks after the company’s high-profile acquisitions of Terns Pharmaceuticals and Cidara Therapeutics to diversify its non-oncology pipeline.
Shifting Alliances: Winners and Losers in the Recurrent Landscape
Merck stands as the clear winner in this regulatory cycle, as the approval provides a fresh revenue stream just as KEYTRUDA’s 2025 sales reached a staggering $31.7 billion. By moving into the platinum-resistant space, Merck is capturing a segment of the market that has been largely underserved. Furthermore, the inclusion of the subcutaneous "Qlex" formulation allows Merck to convert IV patients to a patent-protected delivery method, insulating the franchise against future biosimilar competition in the 2030s.
However, the approval creates a more crowded field for AbbVie Inc. (NYSE: ABBV), whose antibody-drug conjugate (ADC) Elahere (mirvetuximab soravtansine) has been the rising star of the platinum-resistant market since its EU approval in late 2024. While Elahere specifically targets patients with high folate receptor alpha (FRα) expression, KEYTRUDA now offers a viable alternative for the PD-L1 positive population. Patients who are both FRα-high and PD-L1-positive may soon become the center of a "battle for the second line," as clinicians choose between an ADC and an immunotherapy-based regimen.
Meanwhile, established PARP inhibitor leaders like AstraZeneca PLC (NASDAQ: AZN) and GSK plc (NYSE: GSK) may feel indirect pressure. While their blockbusters, Lynparza and Zejula, remain dominant in the first-line and maintenance settings, Merck’s entry into the recurrent space limits the potential for PARP inhibitors to "move down" into later-line resistant populations. Roche Holding AG (OTC: RHHBY), through its foundational drug Avastin (bevacizumab), ironically emerges as a co-beneficiary, as it is often used in combination with KEYTRUDA under the new EC-approved label.
The ADC Revolution and the Strategy of "Pipeline-Driven Resilience"
The approval of KEYTRUDA for ovarian cancer is more than a single-drug victory; it is a microcosm of the broader shift in the oncology industry toward "intelligent" combinations and biomarker-driven selection. The sector is currently undergoing an "ADC revolution," where companies are racing to link potent toxins to targeted antibodies. Merck has lean heavily into this trend, highlighted by its $22 billion partnership with Daiichi Sankyo (OTC: DSKYF), aiming to pair KEYTRUDA with next-generation payloads to extend its clinical utility even further.
This move is also a strategic maneuver against the "patent cliff." With KEYTRUDA's US patents set to expire in 2028 and European protections ending shortly thereafter, Merck is employing a "lifecycle management" masterclass. By layering on new indications like recurrent ovarian cancer and transitioning the market to subcutaneous formulations, Merck aims to retain up to 40% of its market share even after the arrival of biosimilars. This strategy, often referred to as "pipeline-driven resilience," is being closely watched by peers like Bristol-Myers Squibb (NYSE: BMS), who face similar LOE (loss-of-exclusivity) challenges with their own oncology assets.
Regulatory-wise, this approval signals a growing willingness by the European Medicines Agency (EMA) to approve immunotherapies in "niche" populations where the unmet need is high, provided there is a clear biomarker-driven benefit. This sets a precedent for other PD-1/PD-L1 inhibitors to seek similar specialized labels, potentially leading to more fragmented but highly effective treatment algorithms across the oncology landscape.
What Comes Next: Subcutaneous Dominance and ADC Integration
In the short term, Merck’s primary challenge will be the commercial rollout of the subcutaneous formulation across various EU member states, each with its own reimbursement hurdles. The transition from intravenous to subcutaneous administration is critical for Merck’s long-term profitability, as it offers a superior patient experience and a fresh patent life. Analysts expect that by 2027, the majority of new KEYTRUDA starts in the EU will be on the subcutaneous version.
Looking further ahead, the "next frontier" for Merck in ovarian cancer will be the integration of KEYTRUDA with its emerging ADC pipeline. Early-stage trials are already investigating KEYTRUDA in combination with sacituzumab tirumotecan (sac-TMT), a TROP2-directed ADC. If these combinations prove successful, Merck could potentially dominate the entire treatment journey for ovarian cancer, from first-line maintenance to late-stage recurrence, effectively locking out competitors for another decade.
Market opportunities will also arise from the "all-comer" trials currently underway. While the current approval is restricted to the PD-L1 CPS ≥ 1 population, Merck is testing combinations that could potentially work regardless of biomarker status. However, the challenge remains the high cost of these combination therapies, which may face pushback from European health technology assessment (HTA) bodies concerned about the sustainability of healthcare budgets.
A Final Assessment: Securing the Throne
The European Commission’s approval of KEYTRUDA for recurrent ovarian cancer is a definitive win that underscores Merck’s ability to find growth in even the most challenging clinical environments. By delivering a 24% reduction in the risk of death for these patients, Merck has not only advanced the standard of care but also solidified its financial projections for 2026, which see total revenues climbing toward the $67 billion mark.
As we move through the middle of the decade, investors should closely monitor the "conversion rate" of patients from IV to subcutaneous KEYTRUDA, as this will be the truest indicator of Merck’s success in navigating the patent cliff. Additionally, the performance of the non-oncology portfolio—specifically the blockbuster-potential drug Winrevair—will determine if Merck can successfully transition from an oncology-centric firm to a diversified pharmaceutical powerhouse.
For the market, this event proves that the "blockbuster" era of immunotherapy is far from over. Instead, it is evolving into a more complex, biomarker-selective, and delivery-optimized phase. Merck’s latest regulatory win ensures that KEYTRUDA will remain a cornerstone of global oncology for years to come, regardless of the looming competition from biosimilars.
This content is intended for informational purposes only and is not financial advice.
